Containment, Cosmetics, Hormones and Pharmacy

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Containment

Cosmetics

Hormones

Pharmacy

FDA Warns About Compounded Versions of Ozempic and Wegovy

XTalks

JUNE 5, 2023

Ozempic and Wegovy, which contain the active ingredient semaglutide, were approved by the US Food and Drug Administration (FDA). Semaglutide acts as a glucagon-like peptide-1 (GLP-1) receptor agonist, mimicking the GLP-1 hormone released in the gastrointestinal tract after eating. mg and 2.4 mg doses of Wegovy.

FDA Approval

FDA Approval Containment Drugs Pharmacy

U.S. FDA Extends Review of Pfizer’s New Drug Application for PAXLOVID™

Pfizer

DECEMBER 20, 2022

One carton contains five blister packs of PAXLOVID, as co-packaged nirmatrelvir tablets with ritonavir tablets, providing all required doses for a full five-day treatment course. Contraception: Use of ritonavir may reduce the efficacy of combined hormonal contraceptives. For more information, please visit www.PAXLOVID.com.

Drugs

Drugs Licensing Licensing Containment

Clinical Research Informer

FDA Warns About Compounded Versions of Ozempic and Wegovy

U.S. FDA Extends Review of Pfizer’s New Drug Application for PAXLOVID™

Stay Connected